JP2023511471A5 - - Google Patents

Info

Publication number
JP2023511471A5
JP2023511471A5 JP2022523943A JP2022523943A JP2023511471A5 JP 2023511471 A5 JP2023511471 A5 JP 2023511471A5 JP 2022523943 A JP2022523943 A JP 2022523943A JP 2022523943 A JP2022523943 A JP 2022523943A JP 2023511471 A5 JP2023511471 A5 JP 2023511471A5
Authority
JP
Japan
Prior art keywords
formula
exist
alkyldiyl
iii
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022523943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511471A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057356 external-priority patent/WO2021086785A1/en
Publication of JP2023511471A publication Critical patent/JP2023511471A/ja
Publication of JP2023511471A5 publication Critical patent/JP2023511471A5/ja
Pending legal-status Critical Current

Links

JP2022523943A 2019-10-28 2020-10-26 二官能性化合物 Pending JP2023511471A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19205545 2019-10-28
EP19205545.7 2019-10-28
PCT/US2020/057356 WO2021086785A1 (en) 2019-10-28 2020-10-26 Bifunctional compounds

Publications (2)

Publication Number Publication Date
JP2023511471A JP2023511471A (ja) 2023-03-20
JP2023511471A5 true JP2023511471A5 (cg-RX-API-DMAC7.html) 2023-10-31

Family

ID=68382246

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523943A Pending JP2023511471A (ja) 2019-10-28 2020-10-26 二官能性化合物

Country Status (5)

Country Link
US (1) US20230002367A1 (cg-RX-API-DMAC7.html)
EP (1) EP4054724A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023511471A (cg-RX-API-DMAC7.html)
CN (1) CN114599428A (cg-RX-API-DMAC7.html)
WO (1) WO2021086785A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12624044B2 (en) 2019-06-10 2026-05-12 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
JP7508578B2 (ja) * 2020-04-06 2024-07-01 フォグホーン セラピューティクス インコーポレイテッド 化合物及びその使用
CN116490186B (zh) 2020-08-05 2025-10-31 C4医药公司 用于ret的靶向降解的化合物
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
JP2024533990A (ja) 2021-08-09 2024-09-18 ジェネンテック, インコーポレイテッド Brmの調節に使用するためのフェノール誘導体
JP2025502782A (ja) * 2021-12-28 2025-01-28 ボード オブ リージェンツ, ザ ユニヴァーシティー オブ テキサス システム がん治療剤としての強力かつ選択的なsmarca2分解キメラ分子
JP2025506452A (ja) * 2022-02-09 2025-03-11 オーリジーン オンコロジー リミテッド Smarca2及び/又はsmarca4分解剤としての3-置換ピリダジン化合物
AU2023292503A1 (en) * 2022-06-15 2024-10-31 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
CN119384414A (zh) * 2022-06-30 2025-01-28 甘李药业股份有限公司 一种用作smarca2/4抑制剂的化合物及其应用
WO2024064328A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2024064316A1 (en) 2022-09-23 2024-03-28 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 inhibitors and uses thereof
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof
WO2025096976A1 (en) * 2023-11-01 2025-05-08 Cornell University Arid1a is a prognostic marker for aggressive lymphoma transformation and presents a vulnerability to pharmacological inhibition of smarca4/2
WO2025129116A1 (en) * 2023-12-14 2025-06-19 C4 Therapeutics, Inc. Compounds for the targeted degradation of smarca2
WO2026120044A1 (en) * 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019249849C1 (en) * 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
CA3150354A1 (en) * 2019-09-12 2021-03-18 Muralidhara Ramachandra METHOD FOR IDENTIFYING RESPONDERS TO SMARCA2/4 DEGRADATION AGENTS

Similar Documents

Publication Publication Date Title
JP2023511472A5 (cg-RX-API-DMAC7.html)
JP2025160318A5 (cg-RX-API-DMAC7.html)
JP2025160317A5 (cg-RX-API-DMAC7.html)
CN114430739A (zh) Egfr抑制剂、组合物及其制备方法
RU2468016C2 (ru) СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl СО СВЯЗЫВАЮЩИМИ ПАРТНЕРАМИ
JP2019535744A5 (cg-RX-API-DMAC7.html)
JP2022547952A5 (cg-RX-API-DMAC7.html)
JP2024514528A5 (cg-RX-API-DMAC7.html)
JP2022511351A5 (cg-RX-API-DMAC7.html)
JP2022516883A5 (cg-RX-API-DMAC7.html)
AU784243B2 (en) Stable polymorph of N-(3-ethynylphenyl)-6,7-bis (2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
JP2015527318A5 (cg-RX-API-DMAC7.html)
JPH04506522A (ja) 置換イミダゾール
JP2023506805A5 (cg-RX-API-DMAC7.html)
KR101372659B1 (ko) 포스핀 전이 금속 착체, 그의 제조 방법 및 항암제
CN109843872A (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
JP2010511687A5 (cg-RX-API-DMAC7.html)
JP2023519261A5 (cg-RX-API-DMAC7.html)
JP2024544060A5 (cg-RX-API-DMAC7.html)
CN110016015A (zh) 苯甲酰胺和烟酰胺化合物及其使用方法
EP4142798A1 (en) Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention in brain tumors
JP2010520280A5 (cg-RX-API-DMAC7.html)
Ardan et al. Ligand-forced dimerization of copper (I)–olefin complexes bearing a 1, 3, 4-thiadiazole core
JP2020534300A5 (cg-RX-API-DMAC7.html)
JP2022552841A (ja) ポリマー薬物送達コンジュゲートならびにそれを作製および使用する方法